Base IDIQ contract for "prevent preclinical drug development program: toxicology and pharmacology testing"; POP: 1/25/2019-1/24/2024.
Ended Awarded Last action
- Contract number
- 75N91019D00013
- Awardee
-
IIT Research Institute UEI DGBUFQYMKWB5 Part of Illinois Institute Of Technology
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 4 $2,418,859 obligated
Award facts
- Opportunity
- Combined order value
-
- $2,418,859 Current, with exercised options
- $2,662,230 Potential, with all options
- Last date to order 100% complete
- IDV ceiling 3% used
- $74,995,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Cancer Institute (NCI) awarded a $74,995,000 multiple-award indefinite delivery/indefinite quantity (IDIQ) contract called the PREVENT Preclinical Drug Development Program to support preclinical pharmacology, toxicology, and product development services for cancer therapy candidates. The prime contractor, IIT Research Institute (IITRI), is a non-profit division of the Illinois Institute of Technology that specializes in these preclinical services for federal agencies.
Under this IDIQ, NCI has issued several firm-fixed-price task orders to IITRI, including a $656,577 contract for preclinical studies on a nicotine reduction therapy, a $1,412,069 contract for topical skin cancer prevention treatments, a $597,893 contract for COVID-19 related dog studies, and a small $2,399 contract for a kickoff meeting. These task orders leverage IITRI's expertise in non-clinical safety assessments, analytical assay development, and Investigational New Drug (IND) application support to advance promising therapeutic candidates for NCI across various disease areas. The PREVENT IDIQ has a 5-year base period with the potential for two 5-year option periods.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Additional Work (new agreement, FAR part 6 applies) | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91019D00013?
75N91019D00013 was awarded to IIT Research Institute by National Cancer Institute (National Institutes of Health) on January 23, 2019.
How much is contract 75N91019D00013 worth?
Orders under 75N91019D00013 have obligated $2,418,859. Their combined potential value, with all options, is $2,662,230. 75N91019D00013's own ceiling is $74,995,000.
How many orders have been placed under contract 75N91019D00013?
4 orders have been placed under 75N91019D00013, the latest on September 22, 2023.
Who can order from contract 75N91019D00013?
75N91019D00013 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N91019D00013 part of a contract vehicle?
Yes. 75N91019D00013 is part of PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91019D00013 competed?
The extent of competition for 75N91019D00013 was full and open competition. The government received 4 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV